Press Releases

ADC Therapeutics Expands Team

ADC Therapeutics Expands Team
30 September 2014 Lausanne, Switzerland and London, UK, 30 September, 2014 – ADC Therapeutics (ADCT, a portfolio company of Auven Therapeutics) the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced a significant expansion of its team as the Company’s first ADCs enter clinical development. New team members include:

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune
19 May 2014 Lausanne, Switzerland and London, UK, May 19 2014 – ADC Therapeutics (ADCT), an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced today that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research